13-cis-Retinoic acid in the treatment of recurrent glioblastoma multiforme
Open accessAbstract
Basic science and clinical investigations have demonstrated that 13-cis-retinoic acid (cRA) has activity against malignant gliomas. To assess its effectiveness in the setting of recurrent glioblastoma multiforme (GBM), we performed a retrospective analysis of the medical records and neuroimaging results of patients with recurrent GBM who were treated with cRA. The toxicity profile of cRA, response, and effect on progression-free survival from initiation of treatment were end points of our analysis. Eighty-two of 85 patients with a median age of 51 years received at least 1 full cycle of cRA. At the initiation of cRA treatment, the median Karnofsky performance score was 80. All patients had failed conventional radiotherapy. Seven patients were chemonaïve, whereas 75 patients had received some form of chemotherapy. Radiographic partial responses, minor responses, and stable disease were seen in 4%, 8%, and 34% of patients, respectively. Two patients were not assessable. Progression-free survival and overall survival after initiation of cRA were 10.0 and 24.6 weeks, respectively. Six-month progression-free survival was 19% for the entire group. Grade 3 or 4 toxicity developed in 14 patients (16%), one of whom developed pancreatitis and died. The results of this study demonstrate only modest efficacy for cRA therapy in this cohort of heavily pretreated patients with recurrent GBM. This data supports the use of cRA in such patients, but its further evaluation in larger, prospective, controlled studies with or without other noncytotoxic and cytotoxic agents may be warranted.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Results of several clinical trials indicate that 13-cis RA, alone or in combination, seems to be effective at different levels against malignant gliomas, and cancer occurring in the central and peripheral nervous system.
“the results of several clinical trials indicate that 13-cis RA, alone or in combination, seems to be effective at different levels against malignant gliomas115, and cancer occurring in the central and peripheral nervous system116.”
From Advances and challenges in retinoid delivery systems in regenerative and therapeutic medicine (2020) · cites this paper as [115]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Yung, W. K. A., Albright, R. E., Olson, J., Fredericks, R., Fink, K., Prados, M. D., Brada, M., Spence, A., Hohl, R. J., Shapiro, W., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1316 · Cited by 929 · see citing works
Self-citationMulticenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse
Brada, M., Hoang-Xuan, K., Rampling, R., Dietrich, P.-Y., Dirix, L. Y., Macdonald, D., Heimans, J. J., Zonnenberg, B. A., Bravo-Marques, J. M., Henriksson, R., et al. (2001) · Annals of Oncology · doi:10.1023/a:1008382516636 · Cited by 372 · cited 1× · see citing works
“However, studies have shown that improvement or maintenance of healthrelated quality of life issues is associated with objectively assessed responses and PFS in patients with malignant gliomas (Brada et al., 2001; Osoba et al., 2000), which is a further impetus to study cRA.”
BackgroundIrinotecan Therapy in Adults With Recurrent or Progressive Malignant Glioma
Friedman, H. S., Petros, W. P., Friedman, A. H., Schaaf, L. J., Kerby, T., Lawyer, J., Parry, M., Houghton, P. J., Lovell, S., Rasheed, K., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.5.1516 · Cited by 355 · see citing works
Intravenous carboplatin for recurrent malignant glioma: a phase II study.
Yung, W. K. A., Mechtler, L., & Gleason, M. J. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.5.860 · Cited by 180 · see citing works
Self-citationTreatment of Advanced Squamous Cell Carcinoma of the Skin with Isotretinoin
Lippman, S. M., & MEYSKENS, F. L. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-4-499 · Cited by 132 · see citing works
Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid.
Yung, W. K. A., Kyritsis, A. P., Gleason, M. J., & Levin, V. A. (1996) · PubMed · Cited by 122 · see citing works
Self-citationFulton, D. S., Urtasun, R. C., & Forsyth, P. A. (1996) · Journal of Neuro-Oncology · doi:10.1007/bf00177478 · Cited by 121 · see citing works
Benkoussa, M., Brand, C., Delmotte, M.-H., Formstecher, P., & Lefèbvre, P. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.13.4522-4534.2002 · Cited by 112 · see citing works
Understanding CNS remyelination: Clues from developmental and regeneration biology
Franklin, R. J. M., & Hinks, G. L. (1999) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19991015)58:2 · Cited by 110 · see citing works
Scatter factor/hepatocyte growth factor (SF/HGF) content and function in human gliomas
Lamszus, K., Laterra, J., Westphal, M., & Rosen, E. M. (1999) · International Journal of Developmental Neuroscience · doi:10.1016/s0736-5748(99)00008-8 · Cited by 105 · see citing works
Phase II study of paclitaxel in patients with recurrent malignant glioma.
Prados, M. D., Schold, S. C., Spence, A. M., Berger, M. S., McAllister, L. D., Mehta, M. P., GILBERT, M. R., Fulton, D., Kuhn, J. G., Lamborn, K. R., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.8.2316 · Cited by 97 · see citing works
A phase II study of intravenous carboplatin for the treatment of recurrent gliomas
Warnick, R. E., Prados, M. D., Mack, E. E., Chandler, K. L., Doz, F., Rabbitt, J. E., & Malec, M. K. (1994) · Journal of Neuro-Oncology · doi:10.1007/bf01051050 · Cited by 92 · see citing works
Osoba, D., Brada, M., Yung, W. K. A., & Prados, M. D. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00165-9 · Cited by 91 · see citing works
Self-citationPorschen, R., Lohe, B., Hengels, K. J., & Borchard, F. (1989) · Cancer · doi:10.1002/1097-0142(19891215)64:12 · Cited by 75 · see citing works
Self-citationYung, W. K. A., Lotan, R., Lee, P., Lotan, D., & Steck, P. A. (1989) · PubMed · Cited by 67 · see citing works
Self-citationLippman, S. M., Kassler, J. F., Al‐Sarraf, M., Alberts, D. S., Itri, L. M., Mattox, D. E., Hoff, D. D. V., Loescher, L. J., & Meyskens, F. L. (1988) · Investigational New Drugs · doi:10.1007/bf00170781 · Cited by 55 · see citing works
Regulation by retinoic acid of ICAM-1 expression on human tumor cell lines
Bouillon, M., Tessier, P. A., Boulianne, R., Destrempe, R., & Audette, M. (1991) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/0925-4439(91)90091-m · Cited by 47 · see citing works
Chattopadhyay, N., Butters, R. R., & Brown, E. M. (2001) · Molecular Brain Research · doi:10.1016/s0165-3806(00)00154-1 · Cited by 47 · see citing works
Retinoids Inhibit the Oxidative Modification of Protein Kinase C Induced by Oxidant Tumor Promoters
Gundimeda, U., Hara, S., Anderson, W. B., & Gopalakrishna, R. (1993) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1993.1072 · Cited by 35 · see citing works
Effects of retinoic acid and tumor necrosis factor alpha on GL-15 glioblastoma cells
Chambaut‐Guérin, A., Costa, S. L., Lefrançois, T., Fages, C., Gauthereau, X., & Tardy, M. (2000) · Neuroreport · doi:10.1097/00001756-200002070-00033 · Cited by 23 · see citing works
Tallman, M. S. (1994) · PubMed · Cited by 23 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Retinoic acid receptors: From molecular mechanisms to cancer therapy
di Masi, A., Leboffe, L., De Marinis, E., Pagano, F., Cicconi, L., Rochette-Egly, C., Lo-Coco, F., Ascenzi, P., & Nervi, C. (2015) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2014.12.003 · Cited by 403 · see citing works
Retinoic acid signaling and neuronal differentiation
Janesick, A., Wu, S. C., & Blumberg, B. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1815-9 · Cited by 295 · see citing works
The role of bevacizumab in the treatment of glioblastoma
Diaz, R. J., Ali, S. C., Qadir, M. G., de la Fuente, M. I., Ivan, M. E., & Komotar, R. J. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2477-x · Cited by 210 · see citing works
Regulation of glioblastoma stem cells by retinoic acid: role for Notch pathway inhibition
Ying, M., Wang, S., Sang, Y., Sun, P., Lal, B., Goodwin, C. R., Guerrero-Cazares, H., Quinones-Hinojosa, A., Laterra, J., & Xia, S. (2011) · Oncogene · doi:10.1038/onc.2011.58 · Cited by 204 · see citing works
The role of imaging in the management of progressive glioblastoma
Ryken, T. C., Aygün, N., Morris, J., Schweizer, M. L., Nair, R., Spracklen, C. N., Kalkanis, S. N., & Olson, J. J. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1330-0 · Cited by 196 · see citing works
Advances and challenges in retinoid delivery systems in regenerative and therapeutic medicine
Ferreira, R., Napoli, J., Enver, T., Bernardino, L., & Ferreira, L. (2020) · Nature Communications · doi:10.1038/s41467-020-18042-2 · Cited by 138 · see citing works
Accelerator-based BNCT for patients with recurrent glioblastoma: a multicenter phase II study
Kawabata, S., Suzuki, M., Hirose, K., Tanaka, H., Katō, T., Goto, H., Narita, Y., & Miyatake, S. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab067 · Cited by 124 · see citing works
Canadian Recommendations for the Treatment of Glioblastoma Multiforme
Mason, W. P., Maestro, R. F. D., Eisenstat, D. D., Forsyth, P. A., Fulton, D. S., Laperrière, N., Macdonald, D. R., Perry, J., & Thiessen, B. A. (2007) · Current Oncology · doi:10.3747/co.2007.119 · Cited by 123 · see citing works
Salvage therapy with single agent bevacizumab for recurrent glioblastoma
Chamberlain, M. C., & Johnston, S. K. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9957-6 · Cited by 121 · see citing works
Antioxidants in brain tumors: current therapeutic significance and future prospects
Qi, X., Jha, S. K., Jha, N. K., Dewanjee, S., Dey, A., Deka, R., Pritam, P., Ramgopal, K., Liu, W.-T., & Hou, K. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01668-9 · Cited by 100 · see citing works
Neutralization of terminal differentiation in gliomagenesis
Hu, J., Ho, A. L., Yuan, L., Hu, B., Hua, S., Hwang, S. S., Zhang, J., Hu, T., Zheng, H., Gan, B., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1308610110 · Cited by 76 · see citing works
Peñas-Prado, M., Hess, K. R., Fisch, M. J., Lagrone, L. W., Groves, M. D., Levin, V. A., de Groot, J., Puduvalli, V. K., Colman, H., Volas-Redd, G. H., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou155 · Cited by 73 · see citing works
Self-citationBevacizumab for recurrent alkylator‐refractory anaplastic oligodendroglioma
Chamberlain, M. C., & Johnston, S. K. (2009) · Cancer · doi:10.1002/cncr.24179 · Cited by 71 · see citing works
Ellingson, B. M., Wen, P. Y., & Cloughesy, T. F. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox193 · Cited by 67 · see citing works
Modulation of Glioma Risk and Progression by Dietary Nutrients and Antiinflammatory Agents
Kyritsis, A. P., Bondy, M. L., & Levin, V. A. (2011) · Nutrition and Cancer · doi:10.1080/01635581.2011.523807 · Cited by 64 · see citing works
Self-citationChou, A. P., Chowdhury, R., Li, S., Chen, W., Kim, A. J., Piccioni, D. E., Selfridge, J. M., Mody, R. R., Chang, S., Lalezari, S., et al. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs357 · Cited by 63 · see citing works
Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma
Chamberlain, M. C., & Johnston, S. K. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9722-2 · Cited by 62 · see citing works
The Role of Neurodevelopmental Pathways in Brain Tumors
Curry, R., & Glasgow, S. M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.659055 · Cited by 62 · see citing works
Frappaz, D., Schell, M., Thiesse, P., Marec‐Bérard, P., Mottolèse, C., Pérol, D., Bergeron, C., Philip, T. O., Ricci, A. C., Galand-Desmé, S., et al. (2008) · Neuro-Oncology · doi:10.1215/15228517-2008-029 · Cited by 58 · see citing works
Treatment options for glioblastoma
Chamberlain, M. C. (2006) · Neurosurgical FOCUS · doi:10.3171/foc.2006.20.4.12 · Cited by 55 · see citing works
Chakraborty, S., Kanakasabai, S., & Bright, J. J. (2011) · British Journal of Cancer · doi:10.1038/sj.bjc.6606064 · Cited by 54 · see citing works
Levin, V. A., Giglio, P., Puduvalli, V. K., Jochec, J. L., Groves, M. D., Yung, W. K. A., & Hess, K. R. (2005) · Journal of Neuro-Oncology · doi:10.1007/s11060-005-9062-4 · Cited by 45 · see citing works
Self-citationKyritsis, A. P., & Levin, V. A. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1617-9 · Cited by 38 · see citing works
Self-citationOpel, D., Kramer, O. N., Chevalier, M., Bigby, M. E., & Albrecht, J. (2016) · British Journal of Dermatology · doi:10.1111/bjd.15207 · Cited by 36 · see citing works
The role of targeted therapies in the management of progressive glioblastoma
Olson, J. J., Nayak, L., Ormond, D. R., Wen, P. Y., Kalkanis, S. N., & Ryken, T. C. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1339-4 · Cited by 36 · see citing works
Lu, J., Zhang, F., Zhao, D., Hong, L., Min, J., Zhang, L., Li, F., Yan, Y., Li, H., Ma, Y., et al. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9518-4 · Cited by 35 · see citing works
Therapy for recurrent malignant glioma in adults
Mrugała, M. M., Kesari, S., Ramakrishna, N. R., & Wen, P. Y. (2004) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.4.5.759 · Cited by 32 · see citing works
Uruno, A., Noguchi, N., Matsuda, K., Nata, K., Yoshikawa, T., Chikamatsu, Y., Kagechika, H., Harigae, H., Ito, S., Okamoto, H., et al. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.0109025 · Cited by 31 · see citing works
Inhibition of Glioma Development by ASCL1-Mediated Direct Neuronal Reprogramming
Cheng, X.-Y., Tan, Z., Huang, X., Yuan, Y., Qin, S., Gu, Y., Wang, D., He, C., & Su, Z. (2019) · Cells · doi:10.3390/cells8060571 · Cited by 31 · see citing works
Biochemical properties of retinoid-converting enzymes and biotechnological production of retinoids
Hong, S., Kim, K.-R., & Oh, D. (2015) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-015-6830-8 · Cited by 32 · see citing works
Chamberlain, M. C., Tsao-Wei, D. D., & Groshen, S. G. (2005) · Cancer · doi:10.1002/cncr.21582 · Cited by 26 · see citing works
Salvage chemotherapy with CPT‐11 for recurrent temozolomide‐refractory anaplastic astrocytoma
Chamberlain, M. C., Wei‐Tsao, D. D., Blumenthal, D. T., & Glantz, M. (2008) · Cancer · doi:10.1002/cncr.23404 · Cited by 26 · see citing works
Retinoids in the treatment of glioma: a new perspective
Mawson, A. R. (2012) · Cancer Management and Research · doi:10.2147/cmar.s32449 · Cited by 26 · see citing works
Salvage therapy with single agent bendamustine for recurrent glioblastoma
Chamberlain, M. C., & Johnston, S. K. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0612-7 · Cited by 25 · see citing works
Drakulić, D., Schwirtlich, M., Petrović, I., Mojsin, M. M., Milivojević, M., Kovačević‐Grujičić, N., & Stevanović, M. J. (2022) · Cells · doi:10.3390/cells11162530 · Cited by 24 · see citing works
Complications from pharmacotherapy
Nabors, B., Surboeck, B., & Grisold, W. (2016) · Handbook of clinical neurology · doi:10.1016/b978-0-12-802997-8.00014-1 · Cited by 23 · see citing works
Chemotherapy in the treatment of malignant gliomas
Stern, J. I., & Raizer, J. J. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.5.755 · Cited by 23 · see citing works
Hatziagapiou, K., Nikola, O. A., Marka, S., Koniari, E., Kakouri, E., Zografaki, M.-E., Mavrikou, S., Kanakis, C. D., Flemetakis, E., Chrousos, G. P., et al. (2022) · Antioxidants · doi:10.3390/antiox11061074 · Cited by 22 · see citing works
Daily Lifestyle Modifications to Improve Quality of Life and Survival in Glioblastoma: A Review
Travers, S. S., & Litofsky, N. S. (2021) · Brain Sciences · doi:10.3390/brainsci11050533 · Cited by 19 · see citing works
Peñas-Prado, M., Armstrong, T. S., & Gilbert, M. R. (2012) · Handbook of clinical neurology · doi:10.1016/b978-0-444-53502-3.00004-5 · Cited by 19 · see citing works
Retinoid resistance and multifaceted impairment of retinoic acid synthesis in glioblastoma
Campos, B., Weisang, S., Osswald, F., Ali, R., Sedlmeier, G., Bageritz, J., Mallm, J., Hartmann, C. J., von Deimling, A., Popanda, O., et al. (2015) · Glia · doi:10.1002/glia.22849 · Cited by 16 · see citing works
Chemotherapy for malignant glioma
Nicholas, M. K., Lukas, R. V., & Bangalore, S. (2005) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.5.6.s41 · Cited by 13 · see citing works
Fu, M., Zhang, Y., Peng, B., Luo, N., Zhang, Y., Zhu, W., Yang, F. J., Chen, Z., Zhang, Q., Li, Q., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.179530 · Cited by 12 · see citing works
Milanović, D., Sticht, C., Röhrich, M., Maier, P., Grosu, A., & Herskind, C. (2015) · Oncotarget · doi:10.18632/oncotarget.4727 · Cited by 12 · see citing works
Combination of metformin and 9-cis retinoic acid increases apoptosis in C6 glioma stem-like cells
Songthaveesin, C., Sanongdej, W., Limboonreung, T., & Chongthammakun, S. (2018) · Heliyon · doi:10.1016/j.heliyon.2018.e00638 · Cited by 12 · see citing works
An Efficient Commercial Process for the Preparation of Isotretinoin
Salman, M., Babu, S. J., Kaul, V. K., Ray, P. C., & Kumar, N. (2005) · Organic Process Research & Development · doi:10.1021/op0497815 · Cited by 12 · see citing works
Use of high-dose chemotherapy in front-line therapy of childhood malignant glioma
Massimino, M., & Biassoni, V. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.5.709 · Cited by 9 · see citing works
Idiosyncratic Reaction Causing a Rare Side Effect: Isotretenoin-induced Pancreatitis
Atiq, M. U., Raza, A., & Ashfaq, A. A. (2019) · Cureus · doi:10.7759/cureus.6102 · Cited by 9 · see citing works
Combined Treatment of ATRA with Epigenetic Drugs Increases Aggressiveness of Glioma Xenografts.
Schmoch, T., Gal, Z., Möck, A., Mossemann, J., Lahrmann, B., Grabe, N., Schmezer, P., Lasitschka, F., Beckhove, P., Unterberg, A. W., et al. (2016) · PubMed · Cited by 8 · see citing works
Guan, F., Wang, L., Hao, S., Wu, Z., Bai, J., Kang, Z., Zhou, Q., Chang, H., Yin, H., Li, D., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22166 · Cited by 8 · see citing works
Brachyury Is Associated with Glioma Differentiation and Response to Temozolomide
Pinto, F., Costa, Â. M., Andrade, R. P., & Reis, R. M. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00911-9 · Cited by 8 · see citing works
Non-cytotoxic drugs as potential treatments for gliomas
Drappatz, J., & Wen, P. Y. (2004) · Current Opinion in Neurology · doi:10.1097/00019052-200412000-00005 · Cited by 8 · see citing works
Isotretinoin maintenance therapy for glioblastoma: A retrospective review
Chen, S. E., Choi, S. S., Rogers, J. E., Lei, X. J., & de Groot, J. (2013) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155213483348 · Cited by 7 · see citing works
Wion, D., Dreyfus, M., Atifi, M. E., Court, M., Bidart, M., Coutton, C., Leclech, C., Ballester, B., Garcion, E., Bouamrani, A., et al. (2018) · Glioma · doi:10.4103/glioma.glioma_3_18 · Cited by 7 · see citing works
General and neurological complications of targeted therapy
Butowski, N. A., & Chang, S. M. (2012) · Handbook of clinical neurology · doi:10.1016/b978-0-444-53502-3.00033-1 · Cited by 5 · see citing works
Drug Repurposing to Circumvent Chemotherapy Resistance in Brain Tumours
Hill, R., Murray, S. A., Maherally, Z., Higgins, S. C., & Pilkington, G. J. (2016) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-46505-0_6 · Cited by 4 · see citing works
Chimiothérapie et traitements ciblés des glioblastomes
Chinot, O. L., Soulier, P., & Frénay, M. (2010) · Neurochirurgie · doi:10.1016/j.neuchi.2010.07.013 · Cited by 4 · see citing works
Pancréatite aiguë sous acitrétine
Bahtaoui, W., Fetoiki, F. Z. E., Hali, F., & Chiheb, S. (2020) · Annales de Dermatologie et de Vénéréologie · doi:10.1016/j.annder.2020.01.015 · Cited by 4 · see citing works
Glioma Stem Cells in the Context of Oncogenesis
Bengzon, J., Englund, E. M., Salford, L. G., & Fan, X. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-933-8_9 · Cited by 3 · see citing works
Isotretinoin-induced pancreatitis: is it time to definitely recognize it: a case report
Barras, J., Poncin, M., Gast, P., Louis, E., & Loly, J. (2025) · Journal of Medical Case Reports · doi:10.1186/s13256-025-05097-2 · Cited by 2 · see citing works
Raskin, S. I., de Blank, P. M. K., Billups, C. A., Li, Y., Olson, J. M., & Leary, S. E. S. (2025) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaf054 · Cited by 1 · see citing works
Biological therapy of glioblastoma
Dillman, R. O. (2009) · Springer eBooks · doi:10.1007/978-90-481-2289-9_30 · Cited by 1 · see citing works
Recurrent Oligodendroglioma: Treatment with Bevacizumab
Chamberlain, M. C. (2012) · Springer eBooks · doi:10.1007/978-94-007-4213-0_25 · Cited by 1 · see citing works
Retinoids for the Treatment of Glioblastoma
Das, A., Banik, N. L., & Ray, S. K. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0410-2_13 · Cited by 1 · see citing works
How Best to Treat Recurrent Glioma
Levin, V. A. (2012) · CNS Oncology · doi:10.2217/cns.12.3
Self-citationGlioblastomas: are individual therapies required for individual tumors?
Classen, C. F. (2013) · journal of cancer therapeutics and research · doi:10.7243/2049-7962-2-17
Cancer Stem Cells and Brain Cancer: Biology and Therapeutics
Goel, S., Das, S., Hosmane, N. S., Evans, T., Ginn, K. F., & Das, B. C. (2015)
- Authors
- See, S.-J., Levin, V. A., Yung, W.-K. A., Hess, K. R., & Groves, M. D.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Center for Neuro-Oncology (US)
- Corresponding author
- See, Siew-Ju
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-07-01
- Volume
- 6
- Issue
- 3
- Pages
- 253-258
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- PMC
- PMC1871997
- OpenAlex
- W2039322617
- Cited by
- 69
- References
- 21
- Citations by year
- 2025: 2 · 2024: 1 · 2022: 3 · 2021: 3 · 2020: 3 · 2019: 2 · 2018: 2 · 2017: 3 · 2016: 4 · 2015: 5 · 2014: 4 · 2013: 3 · 2012: 6
- FWCI
- 2.22
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Neuro-Oncology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Reproductive Medicine › Ovarian cancer diagnosis and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Keywords
- isotretinoin, recurrent glioblastoma, retinoids, treatment efficacy, progression-free survival, treatment toxicity, pancreatitis, heavily pretreated patients, radiological response
- MeSH terms
- Administration, Oral, Adult, Aged, Aged, 80 and over, Brain Neoplasms, Female, Glioblastoma, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Retrospective Studies, Isotretinoin, Confidence Intervals, Proportional Hazards Models, Survival Analysis, Karnofsky Performance Status
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
